Table 2.

CIMP status and targeted therapy in colorectal cancer.

First Author and Year	Overall Population	Positive (High) Number (Rate)	Markers	Definition of CIMP Status	Methods	TNM Stage	Evaluated Treatment	Response (Evaluation index)
									Zhang XF. (27)	125	27 (21.6%)	CIMP(CACNA1G, IGF2, NEUROG, RUNX3, SOCS1)	≥3/5 loci	MSP	IV	Cetuximab or Panitumumab	A tendency of negative efficacy (PFS, OS)
Gallois C. (31)	1867	275(14.7%)	CIMP(CACNA1G, IGF2, NEUROG, RUNX3, SOCS1)	≥3/5 loci	MSP	III	Cetuximab	A tendency of negative efficacy (OS, DFS, SAR)
Ouchi K. (41)	97(45/52)	17(37.8%) 17(32.7%)	485577 CpG sites	HMCC: CIMP-H LMCC: CIMP-L	Genome-wide DNA methylation	IV	Cetuximab or Panitumumab	Negative efficacy (OS, PFS, DCR,ORR)

CIMP, CpG island methylator phenotype; MSP, methylation-specific polymerase chain reaction; HMCC, Highly methylated colorectal cancer;

LMCC, Low methylated colorectal cancer; DFS, disease-free survival; PFS, progression-free survival; SAR, survival after recurrence; OS, overall survival;

DCR, disease control rate; ORR, objective response rate.